SEC/FDA/FTC Regulatory Watch — Week of May 19–27, 2026

This week's regulatory calendar was unusually active. The SEC both moved to close a three-year-old bribery case involving Adani Group and quietly dismantled a 50-year policy that required settling defendants to stay silent. The FDA cleared the first-ever treatment for a disease that has left patients with no options since its discovery. Here is what happened, who it affects, and where each action leads next.

SEC: two landmark enforcement closures and two rule rewrites

US Capitol dome interior, Washington D.C. — seat of US federal regulatory authority — Federal buildings house the agencies issuing this week's actions. 1

Adani Green bribery case reaches settlement

On May 14, the SEC moved to enter final consent judgments against Gautam Adani (founder of Adani Group) and Sagar Adani (Executive Director of Adani Green Energy), closing the civil fraud case filed in November 2024. 2

The core allegation: while orchestrating a scheme to pay hundreds of millions of dollars in bribes to Indian state electricity officials — in exchange for commitments to purchase power at above-market rates — the two executives signed off on a $750 million bond offering in September 2021 that touted Adani Green's strict anti-corruption compliance. That offering raised over $175 million from U.S. investors.

Without admitting or denying the allegations, Gautam Adani consented to a $6 million civil penalty and Sagar Adani to a $12 million civil penalty, plus permanent injunctions against future violations of Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act. Both judgments are subject to court approval.

Market context: Adani Group's U.S.-listed bonds had already repriced sharply in late 2024 when the original charges were filed. The settlement, while not an admission, removes the overhang of prolonged litigation and may support partial recovery in bond spreads. The DOJ parallel criminal investigation (announced separately in November 2024) remains open, so the SEC closure does not end Adani Group's U.S. legal exposure.

Elon Musk Twitter stake filing — trust-level resolution

On May 4, the SEC filed an amended complaint adding the Elon Musk Revocable Trust as a defendant in the long-running case over the failure to timely disclose a beneficial ownership stake exceeding 5% in Twitter common stock. 3

The SEC simultaneously moved for entry of a consent judgment under which the Trust — without admitting or denying — would pay a $1.5 million civil penalty and be permanently enjoined from future violations of Section 13(d) reporting rules. In return, the SEC committed to dismissing Musk personally once the court enters the Trust judgment, resolving the case in full.

What this means: The $1.5 million penalty is immaterial relative to Musk's wealth. The significance lies in the structural outcome — the SEC obtained a permanent injunction attached to the Trust itself, not just the individual. Any future acquisition through trust vehicles by someone with Musk's profile now carries a well-documented precedent for agency scrutiny.

$26 million HYIP fraud — eight defendants charged

On May 12, the SEC charged two Florida-based firms, Reign Financial International and Berone Capital, along with six individual principals, for running three successive high-yield investment program frauds that raised over $26 million from at least 31 investors. 4

According to the complaint, investors were promised outsized short-term returns backed by opaque financial instruments sourced through "European banks." No such instruments existed. Reign's principals misappropriated investor funds, and Berone's principals spent hedge fund assets on jewelry, luxury cars, and private jet travel. Reign, Johnson, and Mills consented to disgorgement of $1.1 million, prejudgment interest of $372,000, and civil penalties of $1.1 million.

Insider trading: CoStar/Matterport acquisition advance

On May 18, the SEC settled charges against Oskar Elmgart and Raymond Leibman, two New Jersey residents who traded ahead of the April 2024 announcement that CoStar Group had agreed to acquire Matterport. 5

Elmgart bought 260 short-dated out-of-the-money call options; Leibman bought 10,000 Matterport shares. Both obtained the tip from a close family member who worked on the commercial deal. Matterport's stock rose 176% on announcement day. Elmgart netted $63,050 in illicit profits; Leibman had unrealized gains of $30,581. Each faces disgorgement, prejudgment interest, and matching civil penalties.

SEC rule proposals: the biggest policy changes in a generation

Three separate SEC rule actions landed in a single week — two proposed rules and one final rule that removes a 50-year-old restriction.

Rule action	Type	Date	Key change
Optional semiannual reporting	Proposed	May 5	Companies may swap quarterly 10-Qs for a new Form 10-S
Registered offering overhaul	Proposed	May 19	Shelf-offering access, blue-sky preemption, large-filer threshold raised to $2B
No-deny policy rescission	Final rule	May 18	Settling defendants may now publicly contest SEC allegations

US Capitol building exterior, Washington D.C. — The SEC's Atkins-era deregulatory push is reshaping capital markets rules. 6

Optional semiannual reporting (proposed May 5)

SEC Chairman Paul Atkins proposed allowing all public companies to file semiannual reports on a new Form 10-S instead of the current mandatory quarterly 10-Q filings. 7

Under the proposal, companies electing the new form would file one semiannual and one annual report per fiscal year in place of three 10-Qs plus a 10-K. Comment period: 60 days from Federal Register publication.

Affected companies: Roughly every U.S.-listed public company would have the option. The proposal shifts the burden of proof — previously, companies had no choice but to report quarterly. Investor groups are likely to push back, arguing that less frequent disclosure reduces market transparency and increases information asymmetry between insiders and retail investors.

"Transformative reforms" for registered offerings (proposed May 19)

The SEC's broader deregulatory slate 8 would extend shelf-offering access and "well-known seasoned issuer" flexibility to most public companies regardless of public float, allow broker-dealers to publish research on a wider range of issuers, preempt state blue-sky registration requirements across all registered offerings, and raise the large accelerated filer threshold from $700 million to $2 billion in public float. Companies below the new threshold would be exempt from auditor attestation on internal controls over financial reporting.

If adopted, this would be the most sweeping modernization of U.S. registered-offering rules since 2005. Investment banks stand to benefit from expanded research-publishing rights. Smaller public companies gain immediate cost relief on compliance. The public comment period is 60 days.

SEC drops the 50-year "no-deny" settlement rule (final rule, May 18)

The Commission rescinded Rule 202.5(e), which since 1972 had required defendants in settled enforcement actions to agree not to publicly deny the SEC's allegations as a condition of settlement. 9

Chairman Atkins framed the change as a free-speech matter. The rescission also means the Commission will not enforce existing no-deny provisions already in force.

Practical effect: Settling defendants can now publicly contest SEC allegations while still settling. This may lower the friction of settlement — useful for the SEC as it faces a crowded docket — but it introduces a novel dynamic where companies simultaneously pay penalties and run a parallel PR campaign disputing the underlying facts. Defense counsel will likely start building this into settlement playbooks immediately.

FDA: first-ever drug approved for hepatitis delta

US Capitol at dusk — federal regulatory bodies including FDA operate under congressional oversight — Federal oversight agencies including FDA operate under a statutory mandate to protect public health. 10

On May 22, the FDA approved Hepcludex (bulevirtide-gmod) injection, manufactured by Gilead Sciences, as the first-ever treatment for chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. 11

HDV can only infect people who already carry hepatitis B. It causes rapid liver fibrosis, liver cancer, and liver failure. Until this approval, there were no FDA-cleared options.

The pivotal trial (MYR301) showed a combined virologic and biochemical response rate of 48% at week 48 in the Hepcludex arm versus 2% in the delayed-treatment control arm. At week 144, the rate of undetectable HDV RNA was 50% in patients who received immediate treatment. Hepcludex received Breakthrough Therapy Designation, Orphan-Drug Designation, priority review, and was approved under the Accelerated Approval pathway.

Gilead's position: Hepcludex adds to Gilead's existing liver disease portfolio. Given the Orphan designation, Gilead will have seven years of market exclusivity in the U.S. HDV affects an estimated 4.5 to 7% of the approximately 250 million chronic hepatitis B carriers globally, suggesting a commercially meaningful — if niche — opportunity.

FDA launches BHT and ADA food additive reassessments

On May 12, the FDA finalized its new food chemical post-market assessment framework and simultaneously opened requests for information (RFI) on two widely used food additives: butylated hydroxytoluene (BHT) and azodicarbonamide (ADA). 12

BHT is used to prevent fat and oil oxidation in breakfast cereals, frozen pizza, frozen meals, chewing gum, and meat products.
ADA is a dough conditioner and whitening agent in bread and cereal flour; it also appears in food contact materials.

The public comment period for both RFIs closes July 13, 2026. FDA Commissioner Makary framed the initiative as part of a broader "bold food agenda" under the current administration.

Likely impact on food manufacturers: Companies with BHT in their formulas — including major cereal and frozen-food brands — face reformulation pressure if the assessment leads to restrictions. ADA's use in bread products has already drawn scrutiny from consumer groups for years; a formal FDA review elevates the regulatory risk materially. No restrictions are in place yet, but manufacturers should treat the RFI as an early warning.

FDA warning letters: week of May 26

The agency posted a cluster of warning letters on May 26, the most relevant being:

Company	Issuing office	Subject
Sato Pharmaceutical Co., Ltd.	CDER	CGMP/Drugs — adulteration, OTC
GC America, Inc.	CDER	CGMP/Finished pharmaceuticals — adulteration
Alchymars ICM SM Private Limited (India)	CDER	CGMP/Active pharmaceutical ingredient — adulteration
GSC Products, LLC	CDER	Unapproved new drugs / misbranded / OTC
Aja Health and Wellness Inc.	CDER	Unapproved new drug / misbranded
gethyppe.com	Center for Tobacco Products	Family Smoking Prevention and Tobacco Control Act violations

The Sato and Alchymars letters are notable: they involve active pharmaceutical ingredient and OTC drug cGMP failures, the same compliance category that has generated FDA import alerts on Indian manufacturers in recent years. Alchymars is based in India.

FTC: website access limitations this week

Direct access to FTC press releases was unavailable due to JavaScript rendering restrictions during this reporting window. The FTC's enforcement activity will be covered in full in next week's edition, once accessible feeds are restored.

What to watch next week

Court approval of Adani consent judgments — the EDNY must sign off; if approved, the SEC case formally closes.
CoStar/Matterport settlement court entry — routine but marks the formal resolution of the NJ case.
Musk Trust judgment — once entered, the SEC has committed to dismissing Elon Musk personally.
Semiannual reporting proposal — Federal Register publication starts the 60-day comment clock; expect pushback from CFA Institute, investor-rights groups, and institutional proxy advisers.
BHT/ADA comment period — food manufacturers and industry associations will file detailed technical comments.
FTC enforcement actions — Commissioner Ferguson's office has signaled continued focus on tech platforms and gaming; details to follow as access is restored.